+

WO2003045428A3 - Utilisation d'une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur - Google Patents

Utilisation d'une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur Download PDF

Info

Publication number
WO2003045428A3
WO2003045428A3 PCT/EP2002/013531 EP0213531W WO03045428A3 WO 2003045428 A3 WO2003045428 A3 WO 2003045428A3 EP 0213531 W EP0213531 W EP 0213531W WO 03045428 A3 WO03045428 A3 WO 03045428A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified cell
vaccine
technically modified
tumoral disease
disease
Prior art date
Application number
PCT/EP2002/013531
Other languages
German (de)
English (en)
Other versions
WO2003045428A2 (fr
Inventor
John Nieland
Claudia Breidenstein
Adelheid Dinkel
Ute Sartorius
Original Assignee
Medigene Ag
John Nieland
Claudia Breidenstein
Adelheid Dinkel
Ute Sartorius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, John Nieland, Claudia Breidenstein, Adelheid Dinkel, Ute Sartorius filed Critical Medigene Ag
Priority to AU2002356763A priority Critical patent/AU2002356763A1/en
Publication of WO2003045428A2 publication Critical patent/WO2003045428A2/fr
Publication of WO2003045428A3 publication Critical patent/WO2003045428A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'utilisation d'une cellule techniquement modifiée pour traiter une tumeur, la cellule techniquement modifiée n'étant pas dévirée de la tumeur correspondante, ainsi qu'un produit pharmaceutique de prévention, de traitement et/ou de prévention secondaire d'une tumeur contenant une cellule techniquement modifiée.
PCT/EP2002/013531 2001-11-30 2002-11-29 Utilisation d'une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur WO2003045428A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356763A AU2002356763A1 (en) 2001-11-30 2002-11-29 Use of a technically modified cell as a vaccine for treating tumoral disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33449101P 2001-11-30 2001-11-30
US60/334,491 2001-11-30

Publications (2)

Publication Number Publication Date
WO2003045428A2 WO2003045428A2 (fr) 2003-06-05
WO2003045428A3 true WO2003045428A3 (fr) 2003-12-18

Family

ID=23307453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013531 WO2003045428A2 (fr) 2001-11-30 2002-11-29 Utilisation d'une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur

Country Status (2)

Country Link
AU (1) AU2002356763A1 (fr)
WO (1) WO2003045428A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
DE10362104B4 (de) * 2003-08-29 2008-02-14 Kist-Europe Forschungsgesellschaft Mbh Zellprozessor zur Krankheitsbehandlung
RU2354694C2 (ru) 2003-12-30 2009-05-10 Мологен Аг Аллогенное противоопухолевое терапевтическое средство
CN103245787B (zh) * 2012-02-01 2016-01-20 浙江大学 一种肝癌衍生生长因子检测试剂盒的制备方法
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
KR20190100200A (ko) 2016-11-22 2019-08-28 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904786A1 (fr) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Vaccination contre les tumeurs avec l'utilisation des cellules autologues transduits avec un antigène

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904786A1 (fr) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Vaccination contre les tumeurs avec l'utilisation des cellules autologues transduits avec un antigène

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONGHONG WAN ET AL: "DENDRITIC CELLS TRANSDUCED WITH AN ADENOVIRAL VECTOR ENCODING A MODEL TUMOR-ASSOCIATED ANTIGEN FOR TUMOR VACCINATION", HUMAN GENE THERAPY, XX, XX, vol. 8, no. 11, 20 July 1997 (1997-07-20), pages 1355 - 1363, XP000877349, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
AU2002356763A1 (en) 2003-06-10
WO2003045428A2 (fr) 2003-06-05

Similar Documents

Publication Publication Date Title
BG108443A (en) Substituted oxazoliidinones for combinational therapy
MY127290A (en) New use of flibanserin
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MXPA02011288A (es) Tioacetamidas substituidas.
TW200510343A (en) Substituted dihydroquinazolines
MXPA04003796A (es) Tioacetamidas sustituidas.
WO2002079169A8 (fr) Composes de dihydropyrimidine cyano-substitues et leur utilisation pour traiter des maladies
WO2001055111A8 (fr) Composes biaryles, leur preparation et utilisation en therapie
GB0020504D0 (en) Therapeutic method
WO2002011747A3 (fr) Substances biologiques et utilisation de celles-ci dans le traitement de maladies
WO2003045428A3 (fr) Utilisation d'une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EP1303300A4 (fr) Compositions et procedes de traitement de la candidiase
HK1045258A1 (en) Glutathione reductase for therapy and prophylaxis of aids
WO2002076930A3 (fr) Stimulateurs de l'apoptose à médiation des fas à base de diarylurées substituées
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
AU2002214950A1 (en) Determination of the ability of patients to respond to tumour treatment
WO2004012732A3 (fr) Utilisation d'un inhibiteur du proteasome dans le traitement du dysfonctionnement endothelial et/ou dans le cadre d'une therapie a base de proteasome a faible dose
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载